The serum BA levels correlated with the disease severity in NAFLD, whereas the adiponectin levels were inversely correlated [57], supporting that treatment with FXR agonists and/or adiponectin activators may be of help for the prevention of NASH. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.